ストックスクリーナーアプリを入手
32.39
8.47%
2.53
アフターアワーズ：
32.19
-0.20
-0.62%
前日終値:
$29.86
開ける：
$30.4
24時間の取引高:
44,680
Relative Volume:
0.21
時価総額：
$226.65M
収益：
-
当期純損益:
$-4.98M
株価収益率:
-24.58
EPS:
-1.3177
ネットキャッシュフロー:
$-3.85M
1週間 パフォーマンス:
+0.34%
1か月 パフォーマンス:
-12.13%
6か月 パフォーマンス:
+2,789%
1年 パフォーマンス:
+1,407%
1日の値動き範囲:
$29.75
$32.44
1週間の範囲:
$28.21
$34.55
52週間の値動き範囲:
$0.93
$79.02
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
DRUG を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
32.39 | 226.65M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-23 | 開始されました | Piper Sandler | Overweight |
| 2025-01-10 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-01-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-26 | 開始されました | Robert W. Baird | Outperform |
Bright Minds Biosciences Inc (DRUG) 最新ニュース
Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101 - Seeking Alpha
Bright Minds Biosciences (NASDAQ:DRUG) Research Coverage Started at Piper Sandler - Defense World
Piper Sandler sets $93 target for Bright Minds Biosciences stock - MSN
Piper Sandler Initiates Coverage of Bright Minds Biosciences (DRUG) with Overweight Recommendation - MSN
Piper Sandler sets $93 target for Bright Minds Biosciences stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald Predicts DRUG FY2025 Earnings - Defense World
Cantor Fitzgerald Comments on DRUG FY2025 Earnings - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Now Covered by Analysts at Piper Sandler - MarketBeat
This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Learn to Evaluate (DRUG) using the Charts - Stock Traders Daily
Bright Minds Biosciences Appoints New Chief Medical Officer to Advance CNS Therapeutics - MSN
Top 4 Canadian Biotech Stocks (Updated January 2025) - Investing News Network
Head-To-Head Analysis: Bright Minds Biosciences (NASDAQ:DRUG) versus Enlivex Therapeutics (NASDAQ:ENLV) - Defense World
Cantor Fitzgerald Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
HC Wainwright Begins Coverage on Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Coverage Initiated by Analysts at Cantor Fitzgerald - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat
Top 5 Small-cap Biotech Stocks (Updated January 2025) - Investing News Network
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer - The Manila Times
Bright Minds Biosciences (NASDAQ:DRUG) Releases Earnings Results - MarketBeat
Bright Minds Biosciences (DRUG) Finishes the Year with Phenomenal Share Price Increase - Nasdaq
(DRUG) Long Term Investment Analysis - Stock Traders Daily
Best-Performing Small-Cap Stocks of 2024 - Investing.com
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 4.3% – Time to Sell? - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 4.3%Time to Sell? - MarketBeat
(DRUG) Investment Analysis - Stock Traders Daily
Retail investors among Bright Minds Biosciences Inc.'s (CSE:DRUG) largest stockholders and were hit after last week's 10% price drop - Simply Wall St
Baird Initiates Coverage of Bright Minds Biosciences (DRUG) with Outperform Recommendation - MSN
Bright Minds Buosciences Surges 5,900% Last Week. Attention Turning To Cybin ($CYBN) Rallying 23% On Upcoming... - Daily Scanner
Bright Minds Biosciences (NASDAQ:DRUG) Raised to "Strong-Buy" at Baird R W - MarketBeat
Bright Minds initiated at outperform by Baird, Longboard takeover cited - MSN
Bright Minds initiated at outperform by Baird, Longboard takeover cited (NASDAQ:DRUG) - Seeking Alpha
Baird assigns Outperform to Bright Minds stock, sees positive readthrough from recent M&A - Investing.com Nigeria
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting - The Manila Times
Bright Minds to Present BMB-101 Epilepsy Drug Data at Major AES 2024 Conference | DRUG Stock News - StockTitan
Bright Minds Biosciences participates in a conference call with Truist - Nasdaq
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update - The Manila Times
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update - GlobeNewswire Inc.
RA Capital Management, L.P. Acquires New Stake in Bright Minds B - GuruFocus.com
A Billion-Dollar Private Placement Highlights Recent Insider Buying - 24/7 Wall St.
When (DRUG) Moves Investors should Listen - Stock Traders Daily
Cormorant Asset Management's Strategic Acquisition of Bright Min - GuruFocus.com
Bright Minds Biosciences Secures $35 Million Investment - Yahoo Finance
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement - The Manila Times
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank? - Benzinga
Bright Minds Biosciences Inc (DRUG) 財務データ
収益
当期純利益
現金流量
EPS
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):